Novartis to acquire Regulus Therapeutics for up to $1.7 billion
MLex Summary: Novartis has agreed to acquire Regulus Therapeutics, a "clinical-stage biopharmaceutical company focused on developing microRNA therapeutics," for $0.8 billion up front. The deal, which could reach $1.7 billion in...To view the full article, register now.
Already a subscriber? Click here to view full article